Find out about collaboration and partnership opportunities with the Wellcome Sanger Institute that aims to create exceptional healthcare opportunities for everyone from extraordinary science.

1. Impact Through
Innovation
www.sanger.ac.uk/innovations
The Wellcome Sanger Institute,
Cambridgeshire, UK

2. 448Life Sciences and Healthcare
companies based in
Cambridge, UK
£4.55 bn
Total turnover for those
companies (+8% growth on
previous reporting period)
14,983
Employees (+5% growth on
previous reporting period)
The Cambridge Life Science Cluster: A Powerful Innovation Ecosystem

3. The Sanger Institute is located in Cambridge, UK,
within the first bio-cluster in Europe and in close
proximity to Cambridge University and
Addenbrookes Hospital –UK’s clinical centre of
excellence.
In 2018 the Cambridge Cluster housed approx. 450
small and large biomedical companies and over
3,000 in the IT and tech fields.

4. Wellcome Genome Campus: Centre of Excellence in Genomics and Biodata

5. The Sanger Institute is a world leader in genome research
that delivers insights into human and pathogen biology
helping to transform science and medicine by:
• Addressing scientific questions underpinning healthcare issues in
low and middle income countries.
• Producing large-scale sequencing and phenotypic data production
from humans, pathogens and cells.
• Being an ‘ideas factory’; conceiving new questions to address
through genomics and biological science at scale.
• Driving genomics technology development and implementation.
• Innovating in genomic data aggregation and analysis.
• Training scientists and clinicians in genome sciences.
• Leading on global research initiatives with multiple international
partners.
• Being at the centre of a collaborative network of science.
The Genome Campus is a dedicated genomics
and bioinformatics site hosting :
1. Two world-leading Institutes with
complementary functions- the Wellcome Sanger
Institute and the European Bioinformatics Institute.
2. A BioData Innovation Centre hosting 9
companies who share our passion for genomics,
bioinformatics, and its applications for health.
3. A conference and scientific training
organisation whose mission it is to promote
knowledge-sharing amongst scientists as well as
engage the public with the science of genomics.
Our concentration of expertise and data also
draws in a wide range of industrial partners-
GSK, Takeda, Celgene, AstraZeneca to name
just a few.

6. Science at Scale: Unique Combination of Resources and Capabilities

7. The Sanger Institute was established 25 years ago by the
Wellcome Trust, to sequence the first human genome. We were
the single largest contributor to the published DNA sequence achieved
through an international effort. Our research is still steeped in “Big Science”
and a collaborative culture. One example of this is the Open Targets
platform which generates, organises and shares curated information on
genetically validated human targets.
Genomic inquiry requires vast volumes of data, experimental
models and computational power. Our Institute’s unique, scalable
and robust infrastructure delivers – both for us and researchers worldwide.
Sequencing the first human genome took 10 years and $3Bn; at
Sanger we can now sequence the equivalent of 400 human
genomes a day for under $1,000. We share the data, tools and
biological resources we create with scientists across the world.

8. Snapshot of Sanger’s Science

9. Sanger’s 5 areas of scientific
focus
1. Cancer Aging and Somatic Mutation:
Provides leadership in data aggregation and informatics
innovation, develops high-throughput cellular models of
cancer for genome-wide functional screens and drug
testing, and explores somatic mutation’s role in clonal
evolution, ageing and development.
2. Cellular Genetics: Explores human gene function
by studying the impact of genome variation on cell biology.
Large-scale systematic screens are used to discover the
impact of naturally-occurring and engineered genome
mutations in human iPS cells, their differentiated derivatives,
and other cell types.
3. Human Genetics: Applies genomics to population-
scale studies to identify the causal variants and pathways
involved in human disease and their effects on cell biology.
It also models developmental disorders to explore which
physical aspects might be reversible.
4. Parasites and Microbes: Investigates the
common underpinning mechanisms of evolution,
infection and resistance to therapy in bacteria and
parasites. It also explores the genetics of host
response to infection and the role of the microbiota in
health and disease.
5. Tree of Life: Investigates the diversity of
complex organisms found in the UK through
sequencing and cellular technologies. It also
compares and contrasts species’ genome
sequences to unlock evolutionary insights.

10. Sanger’s Translational Output and Successes

11. Most outputs of the translation of Sanger’s research
are applied either as diagnostics, in the development of
biotherapeutics, or as research tools.

12. DIAGNOSTICS (examples)
• Congenica: The ground breaking Deciphering Developmental
Disorders (DDD) programme under which Sanger piloted the use
of genomic technologies for rare disease diagnoses in the clinic
was spun-out to become Congenica. It is now providing clinical
interpretation and diagnostic assistance to Genomics England as
part of the world’s first national (NHS) genomic medicine services.
Supported by international investors it is extending its global reach
in China and the US.
• Sysmex: The large Japanese Dx provider is commercialising
(under a license from Sanger) a paediatric genetic test (Cytosure
TM) by and for the DDD project. (as above).
• Next Gen Dx: A spin-out company based on the Sanger
Institute and Cambridge hospital technologies set up to offer
hospitals a turn-key integrated service for detection of putative
transmission of infection, starting with MRSA.

13. BIOTHERAPEUTICS (examples)
• Open Targets: Is an ambitious public/private alliance of the
Sanger Institute, the European Bioinformatics Institute and 5 large
biopharma companies (GSK, Biogen, Celgene, Sanofi, Takeda)
working to systematically identify and validate novel therapeutic
targets. It recently uncovered WRN as a critical factor in
microsatellite unstable cancers. WRN is now being pursued as a
drug target.
• Kymab: This therapeutic antibody discovery company‘s core
technology was spun out from Sanger and is now one of the very
few UK unicorn companies with a value over a $1Bn.
• Microbiotica: Spun-out from one of Sanger’s pathogen
genomic groups, it uses powerful microbiome analytics to identify
bacteria-based therapeutic and biomarker. It signed a $1/2Bn
partnership with Genentech just 18 months after its formation.

14. TOOLS (examples)
• Merck distributes arrayed CRISPR libraries under license from
the Sanger Institute. These powerful discovery tools are now
installed on 4 continents enabling research globally.
• HIPSCI: A collection of over 800 human iPSC from healthy
donors and rare disease patients available to the research
community in academia and industry.
• Catalogue Of Somatic Mutations In Cancer
(COSMIC) the world’s most comprehensive resource for
exploring the relationship between mutation and cancer is
supporting oncology research with over a 100 small and large
companies licensed to use this curated database.
See also our COSMIC case study:
http://innovationstories.sanger.ac.uk/COSMIC_case_study/index.html

15. Current Partnership Opportunities
• FLIP- One step conditional knock out.
• Isotyper –Antibody
Immunosequencing.
• Melanoma stratification and
combination therapy.
• COSMIC database.
• Tumour organoid collection
(Oesophagus, Colon, Pancreas).
• CRISPR whole genome screening
libraries. *
• CAS9 expressing cancer cell line
collection. *
• 3D organoid models for discovery and
preclinical studies.
• Single cell comparison of disease vs
healthy tissues (liver, skin, gut, lung).
• Strept. pneumonia vaccine antigen
discovery.
• Trypanosoma vaccine (animal health;
neglected disease).
• We’re currently looking for
partners to support early stage
development of Sanger targets
arising from our activities in the
field of IO, inflammation, cancer
and rare disease.

16. The Translation Team at Sanger
Business
Development
Associate
Mariya Chhatriwala,
PhD
Business
Development
Manager
Gary Dillon, PhD
Senior Business
Development
Manager
Emmanuelle
Astoul, PhD
Head of Business
Development and
Technology Transfer
Adrian Ibrahim,
PhD, MBA

17. Get in touch
translationoffice@sanger.ac.uk